Literature DB >> 25246405

Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.

L Davies Forsman1, T Schön2, U S H Simonsson3, J Bruchfeld4, M Larsson5, P Juréen6, E Sturegård7, C G Giske8, K Ängeby9.   

Abstract

We investigated the activity of trimethoprim-sulfamethoxazole (SXT) against Mycobacterium tuberculosis, the pathogen that causes tuberculosis (TB). The MIC distribution of SXT was 0.125/2.4 to 2/38 mg/liter for the 100 isolates tested, including multi- and extensively drug-resistant isolates (MDR/XDR-TB), whereas the intracellular MIC90 of sulfamethoxazole (SMX) for the pansusceptible strain H37Rv was 76 mg/liter. In an exploratory analysis using a ratio of the unbound area under the concentration-time curve from 0 to 24 h over MIC (fAUC0-24/MIC) using ≥ 25 as a potential target, the cumulative fraction response was ≥ 90% at doses of ≥ 2,400 mg of SMX. SXT is a potential treatment option for MDR/XDR-TB.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25246405      PMCID： PMC4249568          DOI： 10.1128/AAC.02995-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Mycobacterium tuberculosis and sulfamethoxazole susceptibility.

Authors:  Wendy Ong; Aina Sievers; David E Leslie
Journal:  Antimicrob Agents Chemother       Date:  2010-06       Impact factor: 5.191

Review 2.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

3.  Tuberculosis and trimethoprim-sulfamethoxazole.

Authors:  Pierre Forgacs; Nancy L Wengenack; Leslie Hall; Sarah K Zimmerman; Mark L Silverman; Glenn D Roberts
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

4.  Imported extensively drug-resistant Mycobacterium tuberculosis Beijing genotype, Marseilles, France, 2011.

Authors:  S Cohen-Bacrie; I Ben Kahla; E Botelho-Nevers; M Million; P Parola; P Brouqui; M Drancourt
Journal:  Euro Surveill       Date:  2011-04-21

5.  Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase.

Authors:  W J Suling; R C Reynolds; E W Barrow; L N Wilson; J R Piper; W W Barrow
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

6.  Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan.

Authors:  Tsi-Shu Huang; Calvin M Kunin; Bo-Shiun Yan; Yao-Shen Chen; Susan Shin-Jung Lee; Wan Syu
Journal:  J Antimicrob Chemother       Date:  2011-11-29       Impact factor: 5.790

7.  Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis.

Authors:  Claudio U Köser; David K Summers; John A C Archer
Journal:  Antimicrob Agents Chemother       Date:  2010-11       Impact factor: 5.191

8.  Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis.

Authors:  Allen C Cheng; Emma S McBryde; Vanaporn Wuthiekanun; Wirongrong Chierakul; Premjit Amornchai; Nicholas P J Day; Nicholas J White; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

9.  Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.

Authors:  Thomas Schön; Pontus Juréen; Christian G Giske; Erja Chryssanthou; Erik Sturegård; Jim Werngren; Gunnar Kahlmeter; Sven E Hoffner; Kristian A Angeby
Journal:  J Antimicrob Chemother       Date:  2009-07-23       Impact factor: 5.790

10.  Validation of a medium-throughput method for evaluation of intracellular growth of Mycobacterium tuberculosis.

Authors:  Daniel Eklund; Amanda Welin; Thomas Schön; Olle Stendahl; Kris Huygen; Maria Lerm
Journal:  Clin Vaccine Immunol       Date:  2010-01-27
View more
  8 in total

1.  Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.

Authors:  Shiqi Xiao; Haidan Guo; Warren S Weiner; Clinton Maddox; Chunhong Mao; Hendra Gunosewoyo; Shaaretha Pelly; E Lucile White; Lynn Rasmussen; Frank J Schoenen; Jeffrey Aubé; William R Bishai; Shichun Lun
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 2.  Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.

Authors:  Yusuke Minato; Joshua M Thiede; Shannon Lynn Kordus; Edward J McKlveen; Breanna J Turman; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

3.  Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Authors:  L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

4.  Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Authors:  Joseph S Cavanaugh; Ruwen Jou; Mei-Hua Wu; Tracy Dalton; Ekaterina Kurbatova; Julia Ershova; J Peter Cegielski
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

Review 5.  Revitalizing antifolates through understanding mechanisms that govern susceptibility and resistance.

Authors:  Shannon Lynn Kordus; Anthony David Baughn
Journal:  Medchemcomm       Date:  2019-05-08       Impact factor: 3.597

6.  An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease.

Authors:  Shashikant Srivastava; Jotam G Pasipanodya; Scott K Heysell; Gunavanthi D Boorgula; Tawanda Gumbo; Pamela J McShane; Julie V Philley
Journal:  J Glob Antimicrob Resist       Date:  2021-12-18       Impact factor: 4.035

7.  Antiinfectives targeting enzymes and the proton motive force.

Authors:  Xinxin Feng; Wei Zhu; Lici A Schurig-Briccio; Steffen Lindert; Carolyn Shoen; Reese Hitchings; Jikun Li; Yang Wang; Noman Baig; Tianhui Zhou; Boo Kyung Kim; Dean C Crick; Michael Cynamon; J Andrew McCammon; Robert B Gennis; Eric Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

8.  Mutations of folC cause increased susceptibility to sulfamethoxazole in Mycobacterium tuberculosis.

Authors:  Ruiqi Wang; Kun Li; Jifang Yu; Jiaoyu Deng; Yaokai Chen
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.